18F-fluorodeoxyglucose positron emission tomography in evaluation of germ cell tumor after chemotherapy

Putra, Lydia Johns; Lawrentschuk, Nathan; Ballok, Zita; Hannah, Anthony; Poon, Aurora; Tauro, A.; Davis, Ian D.; Hicks, Rodney J.; Bolton, Damien; Scott, Andrew M.

doi:10.1016/j.urology.2004.07.024

Cited by 43 publications

(11 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…There are some papers in the literature where they study the clinical impact of PET/CT on the management of the testicular tumors, but the results are controversial as the number of patients are small and is difficult to draw safe conclusions. [1920212223] In the question, if we can rely only on PET/CT in the follow-up of advanced seminoma patients, the answer is negative. However, Ambrosini et al .…”

Section: Discussionmentioning

confidence: 99%

The diagnostic yield of fluorine-18 fluorodeoxyglucose positron emission tomography-computed tomography in recurrent testicular seminoma

et al. 2016

View full text Add to dashboard Cite

The use of positron emission tomography-computed tomography (PET-CT) scan imaging is undoubtedly a significant evolution in oncological urology, although at present of limited use in every day urology practice. The aim of this study is to highlight the indication and diagnostic accuracy of fluorine-18 fluorodeoxyglucose PET/CT in the staging of a patient with metachronous bilateral testicular seminoma, elevated tumor markers, and equivocal conventional imaging findings.

show abstract

Section: Discussionmentioning

confidence: 99%

The diagnostic yield of fluorine-18 fluorodeoxyglucose positron emission tomography-computed tomography in recurrent testicular seminoma

et al. 2016

View full text Add to dashboard Cite

show abstract

“…And another possible reason for false-positive is nonspecific inflammatory processes after chemotherapy Tsatalpas et al, 2002;Albers et al, 2004;Johns Putra et al, 2004). In this regard, it might be of principal importance that we should do the examination before chemotherapy or have an interval of at least 4 weeks after chemotherapy (De Santis et al, 2004;Becherer et al, 2005).…”

Section: Discussionmentioning

confidence: 99%

“…Fluorine-18-fluorodeoxyglucose positron emission tomography (18F-FDG-PET) has been successfully used to evaluate different types of malignant tumors (Saunders et al, 1999;Czernin, 2002;Halfpenny et al, 2002;Johns Putra et al, 2004;Rohren et al, 2004;Chen et al, 2011), like esophagus, thyroid, nasopharyngeal and lung carcinoma (Mutlu et al, 2013;Uzel et al, 2013). FDG-PET is also a valuable tool for assessment of treatment response, and also an indicator of prognosis (Uzel et al, 2013).…”

Section: Introductionmentioning

confidence: 99%

Diagnostic Accuracy of 18F-FDG-PET in Patients with Testicular Cancer: a Meta-analysis

Zhao

Ma²,

Li³

et al. 2014

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

“…In advanced seminoma, management strategy for post‐chemotherapy residual masses is different from that for non‐seminomatous germ cell tumors (NSGCT). In fact residual teratoma is very rare after chemotherapy for seminoma, and positron emission tomography (PET) is very useful for the prediction of residual viable cancer cells 57,58 . FDG (18F‐fluoro‐2‐deoxy‐glucose)‐PET may be a useful modality for advanced seminoma to determine whether surgery for the residual mass should be carried out or not.…”

Section: Role Of Residual Tumor Resection After Chemotherapymentioning

confidence: 99%

Recent strategy for the management of advanced testicular cancer

Nakamura

Miki

2010

Int J of Urology

View full text Add to dashboard Cite

Testicular cancer is the most common cancer in young men and the cure rate has been approximately 80% since the introduction of cisplatin in the 1970s. BEP therapy (including bleomycin, etoposide and cisplatin) has become a standard induction therapy instead of PVB therapy (cisplatin, vinblastin and bleomycin). However, the patients with incomplete responses to cisplatin-based first-line therapy or with relapsed disease have an extremely poor prognosis. For such difficult-to-treat patients, there are some proposed treatment options such as ifosfamide-containing salvage chemotherapy or high-dose chemotherapy (HDCT). HDCT with bone marrow rescue has been carried out as salvage or induction chemotherapy. However, a randomized control trial did not show the superiority to conventional first line therapy or salvage therapy. Therefore, a new anticancer agent was tested for cisplatin-refractory or resistant testicular cancer. The development of combination therapy with new anticancer agents such as paclitaxel and irinotecan seems to be effective for these patients. TIP therapy including paclitaxel, ifosfamide and cisplatin would be a standard second line therapy for the patients with BEP failure. Residual tumor resection including retroperitoneal lymph node dissection integrated with induction and salvage chemotherapy still remains to play an important role to achieving a cure for advanced testicular cancer because there is no modality to predict residual viable cancer cells or teratoma element in the residual tumors. In the present review, we discuss and focus on the recent treatment strategy of advanced testicular cancer.

show abstract

18F-fluorodeoxyglucose positron emission tomography in evaluation of germ cell tumor after chemotherapy

Cited by 43 publications

References 22 publications

The diagnostic yield of fluorine-18 fluorodeoxyglucose positron emission tomography-computed tomography in recurrent testicular seminoma

The diagnostic yield of fluorine-18 fluorodeoxyglucose positron emission tomography-computed tomography in recurrent testicular seminoma

Diagnostic Accuracy of 18F-FDG-PET in Patients with Testicular Cancer: a Meta-analysis

Recent strategy for the management of advanced testicular cancer

Contact Info

Product

Resources

About